Skip to content

The pharmacokinetics and pharmacodynamics of single dose of juhuashuxin tablet on Chinese healthy vonlunteers

The pharmacokinetics and pharmacodynamics of single dose of juhuashuxin tablet on Chinese healthy vonlunteers

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15007224
Enrollment
Unknown
Registered
2015-08-28
Start date
2015-10-22
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

angina pectoris of coronary heart disease

Interventions

four:drug intervention

Sponsors

Xiyuan Hospital, CACMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: aged btween 18 to 50 years, half male andfemale, not exceeding 10 years within the same batch; BMI between 19 to 25, mens weight>50kg, womens weight>45kg, similar body weight within the same batch; no positive signs of physical examination; no clinically abnormity of laboratory inspection andECG test;informed consent andvolunteered to participate the trial.

Exclusion criteria

Exclusion criteria: substance abuser, heavy smoker, alcoholist; subjects who had all sorts of drugs, health care products (including traditional Chinese medicine, homemade wine, etc.) two weeks ago;subjects who participated in clinical trials in recent 4 weeks;subjects who had medication with known organ lesions within 3 months or in current drug use;subjects who donated blood or received blood sampling in clinical trial within 3 months; subjects who had severe disease (including critical illness, infectious disease, food anddrug allergy); subjects who had drug allergy history or with allergic constitution; subjects who had medical history of heart, liver, kidney, digestive tract or nervous andmental system; subjects with positive infection indices; pregnant, breastfeeding andmenstrual women, or women planning pregnancy within 3 months; subjects with gastrointestinal disease or received gastrointestinal operation which may influence the drug absorption; subjects who had bad compliance by investigators judgement.

Design outcomes

Primary

MeasureTime frame
Cmax;????;AUC;T1/2;Ke;Vd;MRT;Cl;coagulation;Glycoprotein IIb/IIIa;eNOS;iNOS;Protein Kinase C;phosphatidylinositol 3-kinase;RAC-alpha serine/threonine-protein kinase;

Secondary

MeasureTime frame
blood routine examination;routine urine examination;stool routine test;blood biochemical examination;ECG;HCG;

Countries

China

Contacts

Public ContactRui Gao
ruigao@126.com+86 010-62835653

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026